Alzheimer’s Drug Deemed Too Expensive for NHS
Eisai and Biogen’s Alzheimer’s drug Leqembi, also known as lecanemab, has been approved by the UK’s Medicines and Healthcare products Regulatory Agency as the first treatment to slow the progression of the disease. However, patients in Britain’s state-run NHS are unlikely to access it after the National Institute for Health and Care Excellence (NICE) deemed it too costly for widespread use.
ПОПУЛЯРНЫЕ ПОСТЫ
Rescuers search for cyclone survivors in devastated Mayotte
Декабрь 17, 2024
“Gilmore Girls” airs for a second season on Hulu
Декабрь 17, 2024
ПОДПИСЫВАЙТЕСЬ НА НАС
ПРЯМАЯ ТРАНСЛЯЦИЯ